Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques

Journal of Virology

Volumn 80, Issue 13, 2006, Pages 6399-6410

  Van Rompay, Koen K A ^a   Singh, Raman P ^a   Heneine, Walid ^c   Johnson, Jeffrey A ^c   Montefiori, David C ^d   Bischofberger, Norbert ^e   Marthas, Marta L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; LYSINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESISTANCE; DRUG SENSITIVITY; EARLY INTERVENTION; IMMUNOSUPPRESSIVE TREATMENT; MACACA; MONKEY DISEASE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT WITHDRAWAL; VIREMIA; VIRUS REPLICATION; VIRUS VIRULENCE;

ADENINE; ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DRUG RESISTANCE, VIRAL; IMMUNE TOLERANCE; MACACA MULATTA; PHOSPHONIC ACIDS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VIRUS REPLICATION;

ANIMALIA; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33745272288     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02308-05     Document Type: Article

References (77)

1. Abbas, U. L., and J. W. Mellors. 2002. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. Proc. Natl. Acad. Sci. USA 99:13377-13378.
2. Angel, J. B. 2001. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. AIDS Reader 11:209-221.
3. 4+ T counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J. Infect. Dis. 181:1808-1812.
4. Borkowsky, W., M. X. Zhan, S. H. Chen, T. Ilmet, A. Kaul, S. Chandwani, M. Rigaud, S. Essajee, C. Gruber, A. Freedman, and K. Krasinski. 2004. Correlation between HIV-specific CD8 cell production of interferon gamma and plasma levels of HIV RNA in perinatally infected pediatric populations. J. Infect. Dis. 190:722-726.
5. Brandt, S. M., R. Mariani, A. U. Holland, T. J. Hope, and N. R. Landau. 2002. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J. Biol. Chem. 277:17291-17299.
6. Cardiello, P. G., E. Hassink, J. Ananworanich, P. Srasuebkul, T. Samor, A. Mahanontharit, K. Ruxrungtham, B. Hirschel, J. Lange, P. Phanuphak, and D. A. Cooper. 2005. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin. Infect. Dis. 40:594-600.
7. Chakraborty, R., R. Musoke, T. Palakudy, A. Cross, and A. D'Agostino. 2003. Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy. Clin. Infect. Dis. 36:1483-1485.
8. Chun, T. W., R. T. J. Davey, D. Engel, H. C. Lane, and A. S. Fauci. 1999. Re-emergence of HIV after stopping therapy. Nature 401:874-875.
9. Decks, S. G. 2001. Durable HIV treatment benefit despite low-level viremia. Reassessing definitions of success or failure. JAMA 286:224-226.
10. Deeks, S. G., R. M. Grant, T. Wrin, E. E. Paxinos, T. Liegler, R. Hoh, J. N. Martin, and C. J. Petropoulos. 2003. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17:361-370.
11. Deeks, S. G., J. N. Martin, E. Sinclair, J. Harris, T. B. Neilands, H. T. Maecker, E. Hagos, T. Wrin, C. J. Petropoulos, B. Bredt, and J. M. McCune. 2004. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J. Infect. Dis. 189:312-321.
12. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
13. DeMaria, M. A., M. Casto, M. O'Connell, R. P. Johnson, and M. Rosenzweig. 2000. Characterization of lymphocyte subsets in rhesus macaques during the first year of life. Eur. J. Haematol. 65:245-257.
14. D'Offizi, G., C. Montesano, C. Agrati, C. Gioia, M. Amicosante, S. Topino, P. Narciso, L. P. Pucillo, G. Ippolito, and F. Poccia. 2002. Expansion of preterminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. AIDS 16:2431-2438.
15. + T cells. Nature 417:95-98.
16. Dybul, M., T.-W. Chun, C. Yoder, B. Hidalgo, M. Belson, K. Hertogs, B. Larder, R. L. Dewar, C. H. Fox, C. W. Hallahan, J. S. Justement, S. A. Migueles, J. A. Metcalf, R. T. Davey, M. Daucher, P. Pandya, M. Baseler, D. J. Ward, and A. S. Fauci. 2001. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc. Natl. Acad. Sci. USA 98:15161-15166.
17. Dybul, M., E. Nies-Kraske, M. Daucher, K. Hertogs, C. W. Hallahan, G. Csako, C. Yoder, L. Ehler, P. A. Sklar, M. Belson, B. Hidalgo, J. A. Metcalf, R. T. Davey, D. M. Rock Kress, A. Powers, and A. S. Fauci. 2003. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J. Infect. Dis. 188:388-396.
18. Dybul, M., E. Nies-Kraske, R. Dewar, F. Maldarelli, C. W. Hallahan, M. Daucher, S. C. Piscitelli, L. Ehler, A. Weigand, S. Palmer, J. A. Metcalf, R. T. Davey, D. M. Rock Kress, A. Powers, I. Beck, L. Frenkel, M. Baseler, J. Coffin, and A. S. Fauci. 2004. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J. Infect. Dis. 189:1974-1982.
19. Evans, D. T., L. A. Knapp, P. Jing, J. L. Mitchen, M. Dykhuizen, D. C. Montefiori, C. D. Pauza, and D. I. Watkins. 1999. Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. Immunol. Lett. 66:53-59.
20. Fagard, C., A. Oxenius, H. Gunthard, F. Garcia, M. Le Braz, G. Mestre, M. Battegay, H. Furrer, P. Vernazza, E. Bernasconi, A. Telenti, R. Weber, D. Leduc, S. Yerly, D. Price, S. J. Dawson, T. Klimkait, T. V. Perneger, A. McLean, B. Clotet, J. M. Gatell, L. Perrin, M. Plana, R. Phillips, and B. Hirschel. 2003. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch. Intern. Med. 163:1220-1226.
21. Ghosn, J., M. Wirden, N. Ktorza, G. Peytavin, H. Ait-Mohand, L. Schneider, S. Dominguez, F. Bricaire, V. Calvez, D. Costagliola, and C. Katlama. 2005. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 19:1643-1647.
22. Greenier, J. L., K. K. A. Van Rompay, D. Monteflori, P. Earl, B. Moss, and M. L. Marthas. 2005. Simian immunodeficiency virus (SIV) envelope quasi-species transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol. J. 2:11. [Online.] http://www.virologyj.com/content/2/1/11.
23. Hel, Z., D. Venzon, M. Poudyal, W.-P. Tsai, L. Giuliani, R. Woodward, C. Chougnet, G. Shearer, J. D. Altman, D. W. Walkins, N. Bischofberger, A. Abimiku, P. Markham, J. Tartaglia, and G. Franchini. 2000. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nature Med. 6:1140-1146.
24. Hodge, S., J. De Rosayro, A. Glenn, I. C. Ojukwu, S. Dewhurst, H. M. McClure, N. Bischofberger, D. C. Anderson, S. A. Klumpp, and F. J. Novembre. 1999. Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj. J. Virol. 73:8630-8639.
25. Johnson, J. A., J. F. Li, L. Morris, N. Martinson, G. Gray, J. McIntyre, and W. Heneine. 2005. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192:16-23.
26. Johnson, J. A., K. K. A. Van Rompay, E. Delwart, and W. Heneine. A sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase. AIDS Res. Hum. Retrovir., in press.
27. Kaye, S., E. Comber, M. Tenant-Flowers, and C. Loveday. 1995. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res. Hum. Retrovir. 11:1221-1225.
28. Knapp, L. A., E. Lehmann, M. S. Piekarczyk, J. A. Urvater, and D. I. Walkins. 1997. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50:657-661.
29. Kumar, A., S. Buch, L. Foresman, N. Bischofberger, J. D. Lifson, and O. Narayan. 2001. Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA. Virology 279:97-108.
30. Lisziewicz, J., E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siciliano, B. Walker, and F. Lori. 1999. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340:1683-1684.
31. Lisziewicz, J., J. Trocio, J. Xu, L. Whitman, A. Ryder, N. Bakare, M. G. Lewis, W. Wagner, A. Pistorio, S. Arya, and F. Lori. 2005. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 19:35-43.
32. Lori, F., M. G. Lewis, J. Xu, G. Varga, D. E. J. Zinn, C. Crabbs, W. Wagner, J. Greenhouse, P. Silvera, J. Yalley-Ogunro, C. Tinelli, and J. Lisziewicz. 2000. Control of SIV rebound through structured treatment interruptions during early infection. Science 290:1591-1593.
33. Lori, F., and J. Lisziewicz. 2001. Structured treatment interruptions for the management of HIV infection. JAMA 286:2981-2987.
34. Lu, W., X. Wu, Y. Lu, W. Guo, and J.-M. Andrieu. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9:27-32.
35. Luzuriaga, K., M. McManus, M. Catalina, S. Mayack, M. Sharkey, M. Stevenson, and J. L. Sullivan. 2000. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J. Virol. 74:6984-6991.
36. Magierowska, M., F. Bernardin, S. Garg, S. Staprans, M. D. Miller, K. K. A. Van Rompay, and E. L. Delwart. 2004. Highly uneven distribution of tenofovir-selected simian immunodeficiency virus drug resistance genotypes in different anatomical sites of rhesus macaques. J. Virol. 78:2434-2444.
37. Mezzaroma, I., M. Carlesimo, E. Pinter, D. Santini Muratori, F. Di Sora, F. Chiarotti, M. G. Cunsolo, G. Sacco, and F. Aiuti. 1999. Clinical and immunologic responses without decrease in virus load in patients after 24 months of highly active antiretroviral therapy. Clin. Infect. Dis. 29:1423-1430.
38. Miller, V., A. N. Phillips, B. Clotet, A. Mocroft, B. Lederberger, O. Kirk, V. Ormaasen, P. Gargalianos-Kakolyris, S. Vella, and J. D. Lundgren. 2002. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J. Infect. Dis. 186:189-197.
39. Monpoux, F., J. Tricoire, M. Lalande, V. Reliquet, B. Bebin, and I. Thuret. 2004. Treatment interruption for virologie failure or as sparing regimen in children with chronic HIV-I infection. AIDS 18:2401-2409.
40. Montaner, J., M. Harris, and R. Hogg. 2005. Structured treatment interruptions: a risky business. Clin. Infect. Dis. 40:601-603.
41. Montefiori, D. C. 2004. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays, p. 12.11.1-12.11.15. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico (ed.), Current protocols in immunology. John Wiley & Sons, Inc., Hoboken, N.J.
42. Nacsa, J., J. Stanton, K. J. Kunstman, W.-P. Tsai, D. I. Watkins, S. M. Wolinsky, and G. Franchini. 2003. Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. Virology 305:210-218.
43. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
44. Ortiz, G. M., M. Wellons, J. Brancato, H. T. T. Vo, R. L. Zinn, D. E. Clarkson, K. Van Loon, S. Bonhoeffer, G. D. Miralles, D. Montefiori, J. A. Bartlett, and D. F. Nixon. 2001. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 98:13288-13293.
45. Oxenius, A., D. A. Price, H. F. Gunthard, S. J. Dawson, C. Fagard, L. Perrin, M. Fischer, R. Weber, M. Plana, F. Garcia, B. Hirschel, A. McLean, and R. E. Phillips. 2002. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. USA 99:13747-13752.
46. Pahar, B., J. Li, T. Rourke, C. J. Miller, and M. B. McChesney. 2003. Detection of antigen-specific T cell interferon γ expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J. Immunol. Methods 282:103-115.
47. Papasawas, E., J. R. Kostman, K. Mounzer, R. M. Grant, R. Gross, C. Gallo, L. Azzoni, A. Foulkes, B. Thiel, M. Pistilli, A. Mackiewicz, J. Shull, and L. J. Montaner. 2004. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLOS Med. 1:e64.
48. Papasawas, E., G. M. Ortiz, R. Gross, J. Sun, E. C. Moore, J. J. Heymann, M. Moonis, J. K. Sandberg, L. A. Drohan, B. Gallagher, J. Shull, D. F. Nixon, J. R. Kostman, and L. J. Montaner. 2000. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J. Infect. Dis. 182:766-775.
49. 3. J. Acquir. Immune Defic. Syndr. 36:791-799.
50. Rosenberg, E. S., M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes, R. L. Eldridge, G. K. Robbins, R. T. D'Aquila, P. J. R. Goulder, and B. D. Walker. 2000. Immune control of HIV-1 after early treatment of acute infection. Nature 407:523-526.
51. Ruiz, L., J. Martinez-Picado, J. Romeu, R. Paredes, M. K. Zayat, S. Marfil, E. Negredo, G. Sirera, C. Tural, and B. Clotet. 2000. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14:397-403.
52. Sabin, C. A., T. Hill, F. Lampe, R. Matthias, S. Bhagani, R. Gilson, M. S. Youle, M. A. Johnson, M. Fisher, G. Scullard, P. Easterbrook, B. Gazzard, A. Phillips, and the UK Collaborative HIV Cohort (UK CHIC) Study Group. 2005. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Br. Med. J. 330:695. (First published 4 March 2005; doi: 10.1136/bmj.38369. 669850.8F.)
53. + T cell responses in young HIV-1-infected infants. J. Immunol. 167:7134-7140.
54. Smith, M. S., L. Foresman, G. J. Lopez, J. Tsay, D. Wodarz, J. D. Lifson, A. Page, C. Wang, Z. Li, I. Adany, S. Buch, N. Bischofberger, and O. Narayan. 2000. Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment of SHIVKU2 infection of rhesus macaques. Virology 277:306-315.
55. + lymphocyte apoptosis in acutely SIV-infected rhesus macaques after short-term antiretroviral treatment. Virology 279:221-231.
56. Tryniszewska, E., J. Nacsa, M. G. Lewis, P. Silvera, D. Monteflori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, K. A. Smith, and G. Franchini. 2002. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169:5347-5357.
57. Van Rompay, K. K. A. 2005. Antiretroviral drug studies in non-human primates: a valid animal model for innovative drug efficacy and pathogenesis studies. AIDS Rev. 7:67-83.
58. Van Rompay, K. K. A., K. Abel, J. R. Lawson, R. P. Singh, K. A. Schmidt, T. Evans, P. Earl, D. Harvey, G. Franchini, J. Tartaglia, D. Montefiori, S. Hattangadi, B. Moss, and M. L. Marthas. 2005. Attenuated poxvirus-based SIV vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38:124-134.
59. Van Rompay, K. K. A., C. J. Berardi, N. L. Aguirre, N. Bischofberger, P. S. Lietman, N. C. Pedersen, and M. L. Marthas. 1998. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 12:F79-F83.
60. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
61. Van Rompay, K. K. A, J. M. Cherrington, M. L. Marthas, P. D. Lamy, P. J. Dailey, D. R. Canfield, R. P. Tarara, N. Bischofberger, and N. C. Pedersen. 1999. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob. Agents Chemother. 43:802-812.
62. Van Rompay, K. K. A., P. J. Dailey, R. P. Tarara, D. R. Canfield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pedersen, and M. L. Marthas. 1999. Early short-term 9-[2-(phosphonomethoxy) propyljadenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73:2947-2955.
63. Van Rompay, K. K. A., J. L. Greenier, K. S. Cole, P. Earl, B. Moss, J. D. Steckbeck, B. Pahar, T. Rourke, R. C. Montelaro, D. R. Canfield, R. P. Tarara, C. J. Miller, M. B. McChesney, and M. L. Marthas. 2003. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SFV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77:179-190.
64. Van Rompay, K. K. A., M. L. Marthas, and N. Bischofberger. 2004. Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion. Antivir. Res. 63:133-138.
65. Van Rompay, K. K. A., M. L. Marthas, J. D. Lifson, C. J. Berardi, G. M. Vasquez, E. Agatep, Z. A. Dehqanzada, K. C. Cundy, N. Bischofberger, and N. C. Pedersen. 1998. Administration of 9-[2-(phosphonomethoxy)propyl] adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res. Hum. Retrovir. 14:761-773.
66. Van Rompay, K. K. A., M. L. Marthas, R. A. Ramos, C. P. Mandell, E. K. McGowan, S. M. Joye, and N. C. Pedersen. 1992. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36:2381-2386.
67. Van Rompay, K. K. A., T. B. Matthews, J. Higgins, D. R. Canfield, R. P. Tarara, M. A. Wainberg, R. F. Schinazi, N. C. Pedersen, and T. W. North. 2002. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J. Virol. 76:6083-6092.
68. Van Rompay, K. K. A, M. B. McChesney, N. L. Aguirre, K. A. Schmidt, N. Bischofberger, and M. L. Marthas. 2001. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J. Infect. Dis. 184:429-438.
69. Van Rompay, K. K. A., M. D. Miller, M. L. Marthas, N. A. Margot, P. J. Dailey, R. P. Tarara, D. R. Canfield, J. M. Cherrington, N. L. Aguirre, N. Bischofberger, and N. C. Pedersen. 2000. Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J. Virol. 74:1767-1774.
70. Van Rompay, K. K. A., M. G. Otsyula, M. L. Marthas, C. J. Miller, M. B. McChesney, and N. C. Pedersen. 1995. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob. Agents Chemother. 39:125-131.
71. Van Rompay, K. K. A., R. Singh, L. Brignolo, J. R. Lawson, K. A. Schmidt, B. Pahar, D. R. Canfield, R. P. Tarara, N. Bischofberger, and M. Marthas. 2004. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. J. Acquir. Immune Defic. Syndr. 36:900-914.
72. + cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol. 78:5324-5337.
73. Vila, J., F. Nugier, G. Bargues, T. Vallet, D. Peyramond, F. Hamedi-Sangsari, and J. M. Seigneurin. 1997. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 350:635-636.
74. + T cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 99:590-599.
75. Walker, A. S., K. Doerholt, M. Sharland, and D. M. Gibb. 2004. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 18:1915-1924.
76. White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.
77. Yerly, S., H. F. Gunthard, C. Fagard, B. Joos, T. V. Perneger, B. Hirschel, and L. Perrin. 2004. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-1953.